Together with our colleagues from Amsterdam and Leiden, we have taken a closer look into the antiinfective and immunomodulating effects our in-house molecule CSY5669 has. We are happy to announce our latest publication in Antimicrobial Agents and Chemotherapy where we target MRSA infections in lungs. CSY5669 could be used as adjunctive therapy in pneumonia caused by MRSA, as it could enhance bacterial eradication while simultaneously limiting inflammation-associated pathology.
News from our Infection Department
